Inmune Bio (INMB) EPS (Diluted) Growth (1y) (2022 - 2026)
Inmune Bio (INMB) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 96.09% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 144.25% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 315.14% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -11.18% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 94.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.10% |
| Mar 31, 2026 | 73.35% |
| Dec 31, 2025 | 53.80% |
| Sep 30, 2025 | 95.83% |
| Jun 30, 2025 | 0.16% |
| Mar 31, 2025 | 55.65% |
| Dec 31, 2024 | -2.16% |
| Sep 30, 2024 | -945.68% |
| Jun 30, 2024 | -170.85% |
| Mar 31, 2024 | -392.89% |
| Dec 31, 2023 | -42.11% |
| Sep 30, 2023 | 97.49% |
| Jun 30, 2023 | -2.76% |
| Mar 31, 2023 | -1.34% |
| Dec 31, 2022 | 38.24% |
| Sep 30, 2022 | -848.75% |